Since the start of 2020 many of the organisations that the Trust supports have been affected by the pandemic, and the Trust has made changes to its grant programmes to provide additional support. During 2020 and 2021 we made awards of more than £1.8m to support the core costs of hospices and smaller charities responding to the pandemic. We also made changes to our research programmes in response to the enormous pressures on researchers working in universities and the NHS.
While the immediate pressures faced by our existing grant-holders have begun to ease, challenges remain. The Trust has tried to be flexible in agreeing revised milestones for projects affected by the pandemic. If you are a grant-holder and are concerned that your project may need to change, or you are having difficulties meeting our normal reporting requirements, do please email the team at [email protected].
The Trustees have continued to review the focus of new awards as the situation has evolved. Our funding for translational medical research and capital funding for research infrastructure has now resumed, and our care programmes have been revised to focus funding on areas where the Trustees believe we can make the greatest difference.
For many charities and NHS organisations, the experience of Covid has highlighted the need to adapt the way in which they deliver care and identified opportunities to build on new care models which they put in place through the pandemic. The Trust has therefore launched a new capital programme to support projects which will improve or integrate models of care, or make care more resilient. The Trust will continue to provide core funding for smaller hospices and charities through our Ann Rylands programme.
Details of all our grants programmes are available here.
Information about other sources of support for local organisations responding to the challenges of the pandemic is available at https://www.grantsonline.org.uk/coronavirus.html.
“We are now in a phase 3 trial and would never have achieved that milestone without the funding from The Sir Jules Thorn Award, which was also important in supporting the successful career development of the young clinicians and scientists who worked for us”.